Liquid Biopsies in Oncology and the Current Regulatory Landscape

There is a profound need in oncology to detect cancer earlier, guide individualized therapies, and better monitor progress during treatment. Currently, some of this information can be achieved through solid tissue biopsy and imaging. However, these techniques are limited because of the invasiveness...

Full description

Saved in:
Bibliographic Details
Published inMolecular diagnosis & therapy Vol. 20; no. 5; pp. 429 - 436
Main Authors Strotman, Lindsay N., Millner, Lori M., Valdes, Roland, Linder, Mark W.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.10.2016
Springer Nature B.V
Subjects
Biomarkers, Tumor
Biomedical and Life Sciences
Biomedicine
Biopsy
Biopsy - methods
Cancer
Cancer Research
Cancer therapies
Conflicts of interest
Disease Management
DNA, Neoplasm - blood
DNA, Neoplasm - genetics
Ethics
Extracellular Vesicles
FDA approval
Government Regulation
Human Genetics
Humans
Laboratories
Laboratory Medicine
Legislation
Metastasis
Molecular Medicine
Neoplasms - blood
Neoplasms - diagnosis
Neoplastic Cells, Circulating - metabolism
Neoplastic Cells, Circulating - pathology
Oncology
Patient safety
Patients
Pharmacotherapy
Practice Guidelines as Topic
Regulation
Review Article
Tumors
Nanoparticle Tracking Analysis
Chronic Traumatic Encephalopathy
Anaplastic Lymphoma Kinase
Circulate Tumor Cell
Extracellular Vesicle
Online AccessGet full text

Cover

More Information
Summary:There is a profound need in oncology to detect cancer earlier, guide individualized therapies, and better monitor progress during treatment. Currently, some of this information can be achieved through solid tissue biopsy and imaging. However, these techniques are limited because of the invasiveness of the procedure and the size of the tumor. A liquid biopsy can overcome these barriers as its non-invasive nature allows samples to be collected over time. Liquid biopsies may also allow earlier detection than traditional imaging. Liquid biopsies include the analysis of circulating tumor cells (CTCs), cell-free nucleic acid (cfNA), or extracellular vesicles obtained from a variety of biofluids, such as peripheral blood. In this review, we discuss different liquid biopsy types and how they fit into the current regulatory landscape.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1177-1062
1179-2000
DOI:10.1007/s40291-016-0220-5